Therapeutics
Developing Next Generation Therapeutics for Healthy Life
Immuno-Oncology
VIEW MORE
-
Direct Killing
-
CTLA4-eADCC
HBM4003
-
CD25-eADCC
HBM1039
-
MSLN-ADC
HBM9033
-
Overcome Immune Suppression
-
CD73
HBM1007
-
B7H7
HBM1020
-
CD200R1
HBM1047
-
SigLec-7/9
HBM1057
-
CD36
HBM1055
Stimulate Immune Cells
T Cell Engager
CD3 HBICE®
-
BCMAxCD3
HBM7020
-
B7H4xCD3
HBM7004
-
CLDN18.2xCD3
AZD5863/HBM7022
4-1BB HBICE®
-
B7H4x4-1BB
HBM7008
-
MSLNx4-1BB
HBM7021
-
CD28 HBICE®
-
PDL1xCD28
HBM7024
-
-
-
BiKE
-
NKp30 HBICE®
-
ROR1xNKp30
HBM7025
-
-
-
BiME/BiDE
-
CD40 HBICE®
-
PDL1xCD40
HBM9027
-
5T4xCD40
HBM7023
-
-
T and NK
-
Other HBICE®
-
CD122xCD132
HBM1040
-
CRTAM
HBM1054
-
Direct Killing:
Deplete Treg cells or Tumor cells by eADCC and next-gen ADC technologyStimulate Immune Cells:
By Immune Cell Engager Bispecific, e.g. HBICE® technologyOvercome Immune Suppression:
Modulate alternative immune evasion pathways beyond PD-(L)1 using H2L2/HCAb/SBC technologyImmunology
VIEW MORE
-
FcRn
HBM9161
-
TSLP
HBM9378
-
SARS-COV-2
HBM9022
Copyright © 2024 Harbour BioMed. All Rights Reserved
沪公网安备31011502401396号
沪ICP备19015946号-1